Pine Valley Investments Ltd Liability Co Increases Position in GSK plc (NYSE:GSK)

Pine Valley Investments Ltd Liability Co increased its stake in GSK plc (NYSE:GSK) by 14.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,823 shares of the pharmaceutical company’s stock after acquiring an additional 1,818 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in GSK were worth $503,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GSK. FMR LLC grew its position in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC grew its position in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its position in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares in the last quarter. Miller Howard Investments Inc. NY purchased a new position in GSK in the fourth quarter worth $23,366,000. Finally, Bridgewater Associates LP lifted its stake in GSK by 107.3% in the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock worth $39,483,000 after purchasing an additional 500,010 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of NYSE:GSK opened at $37.37 on Thursday. The company has a market cap of $77.44 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The company has a 50-day moving average price of $34.83 and a 200-day moving average price of $37.30. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.21%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

Analyst Upgrades and Downgrades

GSK has been the subject of several recent research reports. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.